Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Nu Holdings Ltd — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Nu Holdings Ltd trades at $14.64 (market cap $75.26B). The key difference: Nu Holdings Ltd is far larger — about 77.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Nu Holdings Ltd for 53 Days on average.
| MRVI | NU | |
|---|---|---|
Market Cap | $972.90M | $75.26B |
Volume | 4,325,710 | 60,119,584 |
Sector | Health | Financials |
52-Week High | $9.00 | $18.76 |
52-Week Low | $2.83 | $11.60 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $1.08B | $97.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NU stock trades at $14.93, down 6.75% over 24 hours amid recent volatility. The technical outlook is bullish based on moving averages, though the 6-day RSI at 88.3 suggests overbought conditions. Fundamentally, the company shows strong growth with revenue rising from $3.0B in 2022 to $10.63B in 2025 and net income margin improving to 26.99%. Recent news includes denial of Monzo acquisition talks, causing price swings.
The outlook remains positive given robust fundamentals and analyst consensus, but risks include high valuation multiples, credit concentration, and acquisition speculation volatility. Upside to the $16.53 price target offers potential, though investor caution is warranted near technical resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
